CVS Caremark will update its commercial formularies effective July 1, 2026, to prefer FDA-approved interchangeable biosimilars over certain brand-name drugs, including switching from Stelara to biosimilars Pyzchiva and Yesintek. This change aims to reduce drug costs for clients and members, often resulting in $0 out-of-pocket expenses for patients. The update expands biosimilar coverage in specialty areas like multiple sclerosis and rare blood disorders, supporting affordability and access while maintaining clinical quality. CVS Caremark will provide communication and support to ensure a smooth transition for all stakeholders.
CVS Health has expanded its pharmacy services to include common prescription medications for dogs and cats at all its approximately 9,000 CVS Pharmacy locations across the U.S. This new service allows pet owners to conveniently fill prescriptions for...
The Pacer US Cash Cows 100 ETF (COWZ) gained alongside energy stocks like Exxon Mobil after Brent crude oil prices surged nearly 14% in five days. The ETF, which screens for high free-cash-flow companies, benefits from its roughly 16% energy sector w...
CVS Health has launched its first pharmacy-focused CVS Pharmacy in Houston, aiming to improve community access to medications, immunizations, and pharmacist services. This new format, part of nearly 20 planned locations nationwide, features smaller s...
